InsiderTrades.com logo
Pharis Mohideen net worth and biography
  • Phone
  • Email
  • Website

Pharis Mohideen Biography and Net Worth

Chief Medical Officer of DBV Technologies

Pharis Mohideen serves as Chief Medical Officer and is a member of DBV’s Executive Committee, responsible for continuing development efforts of the Company’s pipeline and bringing potentially innovative new treatments to patients, if approved. Dr. Mohideen brings nearly two decades of industry experience and a track record of multiple drug product approvals. Prior to joining DBV in July 2019, Dr. Mohideen served as Chief Medical Officer for Millendo Therapeutics, Inc., Vice President of Clinical Development at Shionogi Inc., and other clinical and medical leadership roles with Novartis International AG and Bristol Myers-Squibb. Prior to joining the pharmaceutical industry, Dr. Mohideen was an attending physician and assistant professor of medicine at the University of Hawaii, department of internal medicine and served as an investigator on multiple pharmaceutical-sponsored clinical trials.

Dr. Mohideen received his M.D., M.S. in human physiology and B.A. in biology from the University of Hawaii, as well as his M.S. in clinical investigation from Vanderbilt University.

What is Pharis Mohideen's net worth?

The estimated net worth of Pharis Mohideen is at least $1.43 million as of July 29th, 2025. Dr. Mohideen owns 109,649 shares of DBV Technologies stock worth more than $1,430,919 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Mohideen may own. Additionally, Dr. Mohideen receives a salary of $929,400.00 as Chief Medical Officer at DBV Technologies. Learn More about Pharis Mohideen's net worth.

How old is Pharis Mohideen?

Dr. Mohideen is currently 59 years old. There are 4 older executives and no younger executives at DBV Technologies. The oldest executive at DBV Technologies is Mr. Daniel Tassé, CEO & Director, who is 64 years old. Learn More on Pharis Mohideen's age.

What is Pharis Mohideen's salary?

As the Chief Medical Officer of DBV Technologies S.A., Dr. Mohideen earns $929,400.00 per year. The highest earning executive at DBV Technologies is Mr. Daniel Tassé, CEO & Director, who commands a salary of $1,320,000.00 per year. Learn More on Pharis Mohideen's salary.

How do I contact Pharis Mohideen?

The corporate mailing address for Dr. Mohideen and other DBV Technologies executives is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. DBV Technologies can also be reached via phone at (315) 542-7878 and via email at [email protected]. Learn More on Pharis Mohideen's contact information.

Has Pharis Mohideen been buying or selling shares of DBV Technologies?

Pharis Mohideen has not been actively trading shares of DBV Technologies during the last quarter. Most recently, Pharis Mohideen sold 464 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $2.22, for a transaction totalling $1,030.08. Following the completion of the sale, the insider now directly owns 109,649 shares of the company's stock, valued at $243,420.78. Learn More on Pharis Mohideen's trading history.

Who are DBV Technologies' active insiders?

DBV Technologies' insider roster includes Pharis Mohideen (Chief Medical Officer), Timothy Morris (Director), Adora Ndu (Director), and Daniel Soland (Director). Learn More on DBV Technologies' active insiders.

Are insiders buying or selling shares of DBV Technologies?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 1,461 shares worth more than $2,270.56. The most recent insider tranaction occured on July, 29th when insider Pharis Mohideen sold 464 shares worth more than $1,030.08. Insiders at DBV Technologies own 1.4% of the company. Learn More about insider trades at DBV Technologies.

Information on this page was last updated on 7/29/2025.

Pharis Mohideen Insider Trading History at DBV Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2025Sell464$2.22$1,030.08109,649View SEC Filing Icon  
5/22/2025Sell397$1.84$730.48110,113View SEC Filing Icon  
1/30/2025Sell600$0.85$510.00110,510View SEC Filing Icon  
11/25/2024Sell113$2.85$322.0522,222View SEC Filing Icon  
11/21/2024Sell470$2.70$1,269.0022,403View SEC Filing Icon  
7/29/2024Sell357$4.90$1,749.3015,873View SEC Filing Icon  
5/24/2024Sell66$13.60$897.608,115View SEC Filing Icon  
5/22/2024Sell38$13.80$524.408,181View SEC Filing Icon  
5/24/2023Sell46$35.40$1,628.404,943View SEC Filing Icon  
See Full Table

Pharis Mohideen Buying and Selling Activity at DBV Technologies

This chart shows Pharis Mohideen's buying and selling at DBV Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DBV Technologies Company Overview

DBV Technologies logo
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More

Today's Range

Now: $13.05
Low: $12.96
High: $13.42

50 Day Range

MA: $13.96
Low: $9.14
High: $17.00

2 Week Range

Now: $13.05
Low: $2.74
High: $18.00

Volume

978,247 shs

Average Volume

248,892 shs

Market Capitalization

$469.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A